MILBETAB 12,5 MG/125 MG CHEWABLE TABLETS FOR DOGS

Authorised

- Milbemycin oxime
- Praziquantel

Product identification

Medicine name:
MILBETAB 12,5 MG/125 MG CHEWABLE TABLETS FOR DOGS

Active substance:
Milbemycin oxime

Praziquantel

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Milbemycin oxime
12.50 milligram(s) / 1.00 Tablet

Praziquantel

125.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP54AB51

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Spain

Package description:
Box with 1 blister strip of 4 chewable tablets
Box with 2 blister strip of of 5 chewable tablets
Box with of 3 blisters strips of 4 chewable tablets
Box with 5 blister strips of 4 chewable tablets
Box with 6 blisters strips of 4 chewable tablets
Box with 12 blister strips of 4 chewable tablets
1 box with 1 blister of 2 chewable tablets
Box with 2 blister strips of 2 chewable tablets
Box with 1 blister strips of 5 chewable tablets
Box with 5 blisters strips of 2 chewable tablets
Box with of 6 blister strips of 2 chewable tablets
Box with 3 blister strips of 5 chewable tablets
Box with 10 blisters strips of 2 chewable tablets
Box with 12 blister strips of 2 chewable tablets
Box with 5 blister strips of 5 chewable tablets,
Box with 6 blister strips of 5 chewable tablets
Box with 7 blister strips of 5 chewable tablets
Box with 8 blister strips of 5 chewable tablets
Box with 9 blister strips of 5 chewable tablets
Box with 24 blisters strips of 2 chewable tablets
Box with 10 blister strips of 5 chewable tablets

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:
Chanelle Pharmaceuticals Manufacturing Limited

Marketing authorisation date:
23/07/2025

Manufacturing sites for batch release:
Chanelle Pharmaceuticals Manufacturing Limited

Responsible authority:
Spanish Agency Of Medicines And Medical Devices

Authorisation number:
4433 ESP

Date of authorisation status change:
24/07/2025

Reference member state:
France

Procedure number:
FR/V/0488/001

Concerned member states:
Austria Belgium Czechia Finland Germany Hungary Ireland Italy Netherlands Norway Poland Portugal Spain Sweden

Generic of:
600000043292

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

eu-puar-frv0488001-mr-rpe916-en.pdf

15835 FR V 0488 001 DC PuAR.pdf